Literature DB >> 31786803

Analysis of brain metabolites by gas chromatography-mass spectrometry reveals the risk-benefit concerns of prednisone in MRL/lpr lupus mice.

Jia Zhou1, Feilong Lu1, Shan Li1, Meijuan Xie1, Haimei Lu1, Zhijun Xie1, Dehong Wu2, Shuang Wang3, Chengping Wen4, Zheng-Hao Xu5.   

Abstract

OBJECTIVE: Neuropsychiatric systemic lupus erythematosus (NPSLE) is a common cause of disability in systemic lupus erythematosus (SLE). This study aims to investigate the metabolic changes in the hypothalamus and frontal cortex in lupus-prone MRL/lpr mice.
METHODS: Metabolic changes were analyzed using gas chromatography-mass spectrometry (GC-MS).
RESULTS: According to the principal component analysis (PCA), the metabolic profiles were different between the frontal cortex and hypothalamus, but they were comparable between MRL/lpr and MRL/MpJ mice (16 weeks of age). By OPLS-DA, eight cortical and six hypothalamic differential metabolites were identified in MRL/lpr as compared to MRL/MpJ mice. Among these differential metabolites, we found a decrease of N-acetyl-L-aspartate (NAA, a potential marker of neuronal integrity), an increase of pyruvate and a decrease of glutamate in the frontal cortex but not in the hypothalamus. Prednisone treatment (3 mg/kg from 8 weeks of age) relieved the decrease of NAA but further increased the accumulation of pyruvate in the frontal cortex, additionally affected eight enriched pathways in the hypothalamus, and led to significant imbalances between the excitation and inhibition in both the frontal cortex and hypothalamus.
CONCLUSION: These results suggest that the frontal cortex may be more preferentially affected than the hypothalamus in SLE. Prednisone disrupted rather than relieved metabolic abnormalities in the brain, especially in the hypothalamus, indicating that the risk-benefit balance of prednisone for SLE or NPSLE remains to be further evaluated.

Entities:  

Keywords:  Brain; Gas chromatography-mass spectrometry; Glucocorticoids; Lupus; Metabolomics

Year:  2019        PMID: 31786803     DOI: 10.1007/s10787-019-00668-4

Source DB:  PubMed          Journal:  Inflammopharmacology        ISSN: 0925-4692            Impact factor:   4.473


  35 in total

1.  Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry.

Authors:  Warwick B Dunn; David Broadhurst; Paul Begley; Eva Zelena; Sue Francis-McIntyre; Nadine Anderson; Marie Brown; Joshau D Knowles; Antony Halsall; John N Haselden; Andrew W Nicholls; Ian D Wilson; Douglas B Kell; Royston Goodacre
Journal:  Nat Protoc       Date:  2011-06-30       Impact factor: 13.491

2.  MRL/lpr mice have alterations in brain metabolism as shown with [1H-13C] NMR spectroscopy.

Authors:  Jessy J Alexander; Claudia Zwingmann; Richard Quigg
Journal:  Neurochem Int       Date:  2005-07       Impact factor: 3.921

3.  Contemporary treatment of systemic lupus erythematosus: an update for clinicians.

Authors:  Maame B Amissah-Arthur; Caroline Gordon
Journal:  Ther Adv Chronic Dis       Date:  2010-07       Impact factor: 5.091

4.  Accrual of organ damage over time in patients with systemic lupus erythematosus.

Authors:  Dafna D Gladman; Murray B Urowitz; Proton Rahman; Dominique Ibañez; Lai-Shan Tam
Journal:  J Rheumatol       Date:  2003-09       Impact factor: 4.666

Review 5.  Implication of the hypothalamic-pituitary-adrenal axis in the physiopathology of depression.

Authors:  Nicholas Barden
Journal:  J Psychiatry Neurosci       Date:  2004-05       Impact factor: 6.186

6.  Corticosteroids and neuropsychological functioning in patients with systemic lupus erythematosus.

Authors:  S D Denburg; R M Carbotte; J A Denburg
Journal:  Arthritis Rheum       Date:  1994-09

7.  Depression is an early disease manifestation in lupus-prone MRL/lpr mice.

Authors:  Hua-Xin Gao; Sean R Campbell; Min-Hui Cui; Pu Zong; Jong Hee-Hwang; Maria Gulinello; Chaim Putterman
Journal:  J Neuroimmunol       Date:  2009-01-03       Impact factor: 3.478

8.  Accrual of organ damage over time in Argentine patients with systemic lupus erythematosus: a multi-centre study.

Authors:  Gustavo Cassano; Susana Roverano; Sergio Paira; Verónica Bellomio; Eleonora Lucero; Alberto Berman; Alberto Spindler; Rosana Trobo; Luis Fernando Somma; César Graf; Alejandra Barrionuevo; Silvia Papasidero; Oscar Rillo
Journal:  Clin Rheumatol       Date:  2007-04-06       Impact factor: 2.980

9.  Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus-the Hopkins Lupus Cohort.

Authors:  Sarah Al Sawah; Xiang Zhang; Baojin Zhu; Laurence S Magder; Shonda A Foster; Noriko Iikuni; Michelle Petri
Journal:  Lupus Sci Med       Date:  2015-03-11

10.  MetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysis.

Authors:  Jasmine Chong; Othman Soufan; Carin Li; Iurie Caraus; Shuzhao Li; Guillaume Bourque; David S Wishart; Jianguo Xia
Journal:  Nucleic Acids Res       Date:  2018-07-02       Impact factor: 16.971

View more
  1 in total

1.  Analysis of brain metabolites by gas chromatography-mass spectrometry reveals the risk-benefit concerns of prednisone in MRL/lpr lupus mice.

Authors:  Jia Zhou; Feilong Lu; Shan Li; Meijuan Xie; Haimei Lu; Zhijun Xie; Dehong Wu; Shuang Wang; Chengping Wen; Zheng-Hao Xu
Journal:  Inflammopharmacology       Date:  2019-11-30       Impact factor: 4.473

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.